ClinicalTrials.gg
RecruitingNCT02634645Updated Feb 28, 2025

TREAT-BE Study (Treatment with Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)

An observational study in Barrett's Esophagus and Esophageal Cancer, sponsored by University of Colorado, Denver. Recruiting at 4 sites in United States. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by University of Colorado, Denver · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 209 studies in Barrett Esophagus with a site in United States — 38 open to participants now, 48 under way, none of them phase 3. Barrett Esophagus · United States.

Planned enrollment
4th of 86
5,000 · median 123
Started
2015
with 9 others
Observational
87 of 209
22 open now
Primary completion
2027-01
later than 12 of 47 live
Registered
118th of 209
by date
Lead sponsor
6 of 209
University of Colorado, Denver

Among the 209 studies in Barrett Esophagus with a site in United States, this one is the 4th largest by planned enrollment of the 86 observational ones that give a count, is one of 10 that started in 2015, is one of 87 observational ones, reaches primary completion later than 12 of the 47 other live ones, and was the 118th registered.

Barrett Esophagus

312 studies on the registry are indexed under Barrett Esophagus; 60 are open to participants now.

Browse Barrett Esophagus studies →

Open to participants now

38 of the 209 studies in Barrett Esophagus with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 44 Barrett Esophagus studies recruiting now, 31 (70%) set no upper age limit and 2 (5%) stop at 75 or younger; 4 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Barrett Esophagus with a site in United States, or all of them as a file.
02

Study summary

A prospective outcomes study in patients with and esophageal cancer (EAC) and Barrett's esophagus (BE) associated neoplasia being evaluated for endoscopic eradication therapy (EET).

Read the detailed description

Patients will be enrolled in this study at the participating centers when evaluated in gastro-intestinal (GI) clinics and endoscopy suites. Initial evaluation of patients will include collection of data on demographics, assessment of risk factors such as smoking, metabolic syndrome, family history and detailed medication history, and past surgical history. All patients will be complete questionnaires regarding Gastroesophageal Reflux Disease (GERD) symptoms, GERD related quality of life (QOL) and overall health related QOL. Details of all previous endoscopic and surgical evaluation along with histopathology data will be documented. Patients undergoing endoscopic evaluation at the participating centers will have their endoscopic and histopathology results documented. This will include data collection regarding use of advanced imaging techniques, details regarding tissue acquisition, EET and adverse events. Patients undergoing esophagectomy will have surgical details documented along with complications related to surgery. Similarly, details regarding chemoradiation treatments will be documented .

03

Conditions studied

  • Barrett's Esophagus
  • Esophageal Cancer
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Formation of a multi-site prospective database of patients with BE associated neoplasia referred for consideration for EET and EAC.

Women and minorities will be included as they are found to have BE, BE related dysplasia, and EAC. It is well recognized that the majority of patients diagnosed with BE are white males. However, we will actively seek to include all women and minorities with a diagnosis of BE associated neoplasia for the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Barrett's related neoplasia and dysplasia. Patients with esophageal cancer

Exclusion criteria

Exclusion Criteria:

  • Patients with squamous cell carcinoma
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with Barrett's Esophagus

    Patients with non-dysplastic Barrett's esophagus, patients with Barrett's related dysplasia which includes low-grade dysplasia, high-grade dysplasia and intramucosal cancer who will be evaluated and treated with endoscopic eradication therapies (EET).

    Procedure: Endoscopic eradication therapies (EET)

  • Patients with invasive esophageal cancer

    Patients with invasive esophageal cancer who will be treated with surgery (esophagectomy), chemotherapy, radiation, and palliative treatment modalities.

    Procedure: Esophagectomy · Drug: Chemotherapy · Radiation: Radiation

Interventions

  • ProcedureEndoscopic eradication therapies (EET)

    Endoscopic eradication therapies (EET) includes endoscopic mucosal resection (EMR), which describes the process by which the area most likely to harbor highest grade of dysplasia/neoplasia is removed; radiofrequency ablation (RFA), which describes the process by which Barrett's segments are removed via burning/ablation; and cryotherapy.

  • ProcedureEsophagectomy

    The esophagus is surgically removed

  • DrugChemotherapy

    Chemical substances are used to treat cancer

  • RadiationRadiation

    Cancer cells are destroyed by radiation therapy.

06

What researchers measure

Primary outcomes

  1. Overall improvement of patient outcomes in patients treated with endoscopic eradication therapy (EET).

    A systematic, prospective collection of data from a large cohort of patients with BE and EAC undergoing EET will provide useful data in effort to improve overall patient outcomes.

    Time frame: 5 years

Secondary outcomes

  1. Long-term effectiveness or durability of EET in BE related neoplasia.

    To report on long-term effectiveness or durability of EET in BE related neoplasia.

    Time frame: 5 years

  2. Quality of life (QOL) in patients undergoing endoscopic eradication therapies for Barrett's associated neoplasia

    To assess quality of life (QOL) using the Promise GERD HRQL (Health Related Quality of Life) questionnaire in patients undergoing endoscopic eradication therapies for Barrett's associated neoplasia

    Time frame: 5 years

  3. Recurrence rate of neoplasia

    To report on the recurrence rate of neoplasia (defined as number of patients with established eradicated neoplasia post-EET who are found to have recurrent intestinal metaplasia on subsequent surveillance biopsies)

    Time frame: 5 years

  4. Recurrence rate of intestinal metaplasia

    To report on the recurrence rate intestinal metaplasia (defined as number of patients with established eradicated intestinal metaplasia and/or neoplasia post-EET who are found to have recurrent intestinal metaplasia on subsequent surveillance biopsies).

    Time frame: 5 years

  5. Recurrence rate based on baseline dysplasia, Barrett's length, and treatment modality

    Percentage of patients of different baseline Barrett's treatment modalities (EMR vs. RFA vs. cryotherapy) whose Barrett's is persistent despite treatment and/or recurs post-eradication. Percentage of patients of different baseline Barrett's lengths whose Barrett's is persistent despite treatment and/or recurs post-eradication. Percentage of patients of different baseline Barrett's histologies (i.e. high grade dysplasia/intramucosal cancer vs. low grade dysplasia) whose Barrett's is persistent despite treatment and/or recurs post-eradication.

    Time frame: 5 years

  6. Persistence rate based on baseline dysplasia, Barrett's length, and treatment modality

    Percentage of patients of different baseline Barrett's treatment modalities (EMR vs. RFA vs. cryotherapy) whose Barrett's is persistent despite treatment and/or recurs post-eradication. Percentage of patients of different baseline Barrett's lengths whose Barrett's is persistent despite treatment and/or recurs post-eradication. Percentage of patients of different baseline Barrett's histologies (i.e. high grade dysplasia/intramucosal cancer vs. low grade dysplasia) whose Barrett's is persistent despite treatment and/or recurs post-eradication.

    Time frame: 5 years

  7. Adverse event rates associated with EET for BE associated neoplasia and EAC.

    To determine adverse event rates associated with EET for BE associated neoplasia and EAC.

    Time frame: 5 years

  8. Determine health-care utilization including endoscopic surveillance practices and outcomes in BE patients with and without neoplasia

    Number of BE patients (both with and without neoplasia) in the general population who receive various endoscopic interventions (including RFA, cryotherapy, EMR, endoscopic surveillance)

    Time frame: 5 years

  9. Magnitude of risk factors for BE.

    The number of BE patients who fall into specific age cohorts; the number of BE patients who are male/female; the number of BE patients who fall into specific BMI cohorts; the number of BE patients who have used tobacco and/or currently use tobacco; the number of BE patients who have GERD symptoms; the number of BE patients who have metabolic syndrome; the number of BE patients who take aspirin, NSAIDS, anti-hyperglycemic medications, and/or statins.

    Time frame: 5 years

  10. Magnitude of risk factors for BE related neoplasia.

    The number of BE related neoplasia patients who fall into specific age cohorts; the number of BE related neoplasia patients who are male/female; the number of BE related neoplasia patients who fall into specific BMI cohorts; the number of BE related neoplasia patients who have used tobacco and/or currently use tobacco; the number of BE related neoplasia patients who have GERD symptoms; the number of BE related neoplasia patients who have metabolic syndrome; the number of BE related neoplasia patients who take aspirin, NSAIDS, anti-hyperglycemic medications, and/or statins.

    Time frame: 5 years

  11. Magnitude of risk factors for EAC.

    The number of EAC patients who fall into specific age cohorts; the number of EAC patients who are male/female; the number of EAC patients who fall into specific BMI cohorts; the number of EAC patients who have used tobacco and/or currently use tobacco; the number of EAC patients who have GERD symptoms; the number of EAC patients who have metabolic syndrome; the number of EAC patients who take aspirin, NSAIDS, anti-hyperglycemic medications, and/or statins.

    Time frame: 5 years

  12. Impact of endoscopic and radiologic imaging modalities.

    Number of patients whose treatment plan changes due to endoscopic ultrasound and/or Computed Tomography-Positron Emission Tomography (CT-PET) findings

    Time frame: 5 years

  13. Median time to recurrence of intestinal metaplasia

    To report on the median time to recurrence (measured median amount of months between complete eradication and recurrence of intestinal metaplasia).

    Time frame: 5 years

  14. Median time to recurrence of neoplasia

    To report on the median time to recurrence (measured median amount of months between complete eradication and recurrence of neoplasia).

    Time frame: 5 years

07

Study locations

4 of 4 sites recruiting
08

References and documents

Publications

  • Wani S, Han S, Kushnir V, Early D, Mullady D, Hammad H, Brauer B, Thaker A, Simon V, Ezekwe E, Hollander T, Wood M, Rastogi A, Edmundowicz S, Muthusamy VR, Komanduri S. Recurrence Is Rare Following Complete Eradication of Intestinal Metaplasia in Patients With Barrett's Esophagus and Peaks at 18 Months. Clin Gastroenterol Hepatol. 2020 Oct;18(11):2609-2617.e2. doi: 10.1016/j.cgh.2020.01.019. Epub 2020 Jan 23. PubMed 31982610 ↗
  • Omar M, Thaker AM, Wani S, Simon V, Ezekwe E, Boniface M, Edmundowicz S, Obuch J, Cinnor B, Brauer BC, Wood M, Early DS, Lang GD, Mullady D, Hollander T, Kushnir V, Komanduri S, Muthusamy VR. Anatomic location of Barrett's esophagus recurrence after endoscopic eradication therapy: development of a simplified surveillance biopsy strategy. Gastrointest Endosc. 2019 Sep;90(3):395-403. doi: 10.1016/j.gie.2019.04.216. Epub 2019 Apr 17. PubMed 31004598 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Jan 2027 and a completion of Jan 2027. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2015
First posted
Dec 18, 2015
Start
Jan 2015
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02634645
Collaborators
Northwestern University Feinberg School of Medicine, University of California, Los Angeles, H. Lee Moffitt Cancer Center and Research Institute, California Pacific Medical Center
Responsible party
Sponsor
First posted
Dec 18, 2015
Start date
Jan 2015
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Feb 28, 2025

Study contacts

Sachin Wani, MD
Contact
sachin.wani@ucdenver.edu
720-848-2786
Violette C Simon, MS
Contact
violette.simon@ucdenver.edu
303-724-6670
Sachin Wani, MD
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion